https://doi.org/10.5812/kowsar.1735143X.690

Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients

authors:

avatar Zakieh Rostamzadeh Khameneh 1 , avatar Nariman Sepehrvand 2 , * , avatar Sima Masudi 3

Department of Microbiology and Immunology, Urmia University of Medical Sciences, IR Iran
Students Research Committee, Deputy for Research Affairs, Urmia University of Medical Sciences, Nariman256@gmail.com, IR Iran
Deputy for Research Affairs, Shahid Beheshti University of Medical Sciences, IR Iran
Hepatitis Monthly: Vol.11, issue 8; 646-651
article type: Research Article
received: November 16, 2010
accepted: April 16, 2011

How To Cite Rostamzadeh Khameneh Z, Sepehrvand N, Masudi S. Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients. Hepat Mon. 2011;11(8): 646-651. https://doi.org/10.5812/kowsar.1735143X.690.

Abstract

Background: Renal transplant recipients are known to be susceptible to viral infections, with more severe clinical presentations compared to healthy persons. Hepatitis E is generally a self-limited disease, which is caused by hepatitis E virus. Recently, hepatitis E has become more important in organ transplant recipients, because of new findings regarding the potential for chronic infections in this patient group.
Objectives: This study aimed to evaluate the seroprevalence of anti-HEV IgG among kidney transplant recipients in Urmia, in the north-western region of Iran.
Patients and Methods: 91 patients were selected randomly from amongst patients who had undergone kidney transplantation in Urmia, Iran. Each patient was tested for the presence of anti-HEV IgG antibody using an enzyme-linked immunosorbent assay (ELISA, Dia.Pro; Diagnostic Bioprobes, Italy).
Results: 28 subjects (30.8%) were seropositive for anti-HEV IgG. Seropositive patients were generally older than seronegative patients (P = 0.009). There was no correlation between HEV infection and the level of education (P = 0.206), the history of blood transfusion (P = 0.164), or history of pre-transplantation hemodialysis (P = 0.228). There was no significant difference in the serum alanine aminotransferase (ALT) levels of the anti-HEV seropositive and seronegative patients. Multinomial logistic regression analysis indicated no significant relationship between HEV infection and increase in ALT levels, even after controlling for treatment with azathioprine (P = 0.79, OR = 1.12; 95% CI: 0.45-2.76).
Conclusion: The anti-HEV IgG antibody has a high prevalence in Iranian kidney transplant recipients, and it is significantly higher in comparison with previous studies in the general population or in hemodialysis patients. 

 

  • Implication for health policy/practice/research/medical education:
    The prevalence rate of anti-HEV IgG in transplant recipients is independent of its prevalence in the general population. In the setting of transplant recipients, the clinicians should not look merely for clinical evidence to consider hepatitis E.
  • Please cite this paper as:
    Khameneh ZR, Sepehrvand N, Masudi S. Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients. Hepat Mon. 2011;11(8):646-51. [DOI: 10.5812/kowsar.1735143X.690]

 © 2011 Kowsar M.P.Co. All rights reserved.

 

Full Text

Full text is available in PDF